OncoMatch/Clinical Trials/NCT04981509
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
Is NCT04981509 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including Atezolizumab and Bevacizumab for hereditary leiomyomatosis and renal cell carcinoma.
Treatment: Atezolizumab · Bevacizumab · Erlotinib · Sodium Fluoride F-18 — This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosis and kidney cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Bevacizumab is in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumors. This may slow the growth and spread of tumors. Erlotinib is in a class of medications called kinase inhibitors. It works by blocking the action of a protein called EGFR that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Combination therapy with bevacizumab, erlotinib, and atezolizumab may stabilize or shrink advanced hereditary leiomyomatosis and kidney cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Other
Cancer type
Renal Cell Carcinoma
Disease stage
Required: Stage III, IV (other)
Metastatic disease required
advanced RCC with measurable disease
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: bevacizumab in metastatic/advanced setting (bevacizumab)
no prior bevacizumab therapy in the metastatic/advanced setting
Cannot have received: PD-1 or PD-L1 inhibitor in metastatic/advanced setting
No prior treatment with PD-1 or PD-L1 inhibitors in the metastatic/advanced setting
Lab requirements
Blood counts
Absolute neutrophil count >= 1,000/mcL; Platelets >= 100,000/mcL
Kidney function
Glomerular filtration rate (GFR) >= 30 mL/min/1.73 m^2; pediatric creatinine thresholds specified
Liver function
Total bilirubin <= 1.5 x institutional ULN (< 3 x upper limit of reference range in patients with known/suspected Gilbert's disease); AST/ALT <= 2.5 x institutional ULN (or <= 5 x upper limit of reference range if considered to be related to liver or bone metastases by PI); Alkaline phosphatase <= 2.5 x institutional ULN (or <= 5 x upper limit of reference range if considered to be related to liver or bone metastases by PI)
Cardiac function
Patients with cardiac disease or history of cardiotoxic agents should be class 2B or better by New York Heart Association Functional Classification
Absolute neutrophil count >= 1,000/mcL; Platelets >= 100,000/mcL; Total bilirubin <= 1.5 x institutional ULN (< 3 x upper limit of reference range in patients with known/suspected Gilbert's disease); AST/ALT <= 2.5 x institutional ULN (or <= 5 x upper limit of reference range if considered to be related to liver or bone metastases by PI); Alkaline phosphatase <= 2.5 x institutional ULN (or <= 5 x upper limit of reference range if considered to be related to liver or bone metastases by PI); GFR >= 30 mL/min/1.73 m^2; cardiac risk assessment required
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Rutgers Cancer Institute of New Jersey · New Brunswick, New Jersey
- NYU Langone Hospital - Long Island · Mineola, New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone · New York, New York
- Ohio State University Comprehensive Cancer Center · Columbus, Ohio
- University of Pittsburgh Cancer Institute (UPCI) · Pittsburgh, Pennsylvania
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04981509 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior bevacizumab in metastatic/advanced setting, PD-1 or PD-L1 inhibitor in metastatic/advanced setting disqualifies patients from enrollment.
What disease stage is eligible?
Stage III or IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages